Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1369–1404
Headlines
1917
Sources here
21
Companies here
14
Current section United States Drug Manufacturers - General news

Chronological news

Earlier headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingView Earnings Main company 🇺🇸 United States

Merck & Co., Inc. Revenue Breakdown – VIE:MRK

Merck & Co., Inc. (VIE:MRK) generated €55.35 billion in revenue last year, with its Pharmaceutical segment contributing the majority at €49.50 billion. The United States was the largest regional contributor, accounting for €31.09 billion. This data provides a breakdown of the company's financial performance …

MRK main company
Sharemaestro market context Trend signal active 52 weeks +60.7% MRK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇺🇸 United States

Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO

(Bloomberg) -- Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering. Most Read from Bloomberg Retina Chip Designed to Restore Sight to Go on Sale in Europe …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3% LLY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
BioPharma Dive Market update Main company 🇺🇸 United States

Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

Novo Nordisk has escalated its legal dispute with Eli Lilly, seeking an injunction to stop allegedly "misleading" obesity drug advertisements. Meanwhile, Johnson & Johnson reported strong results for a multiple myeloma drug combination, Revolution Medicines' pancreatic tumor medicinedaraxonrasib was accepted for FDA review, and …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3% LLY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
BioPharma Dive Deals and strategy Main company 🇺🇸 United States

Sanofi halts development of troubled immune drug in eczema

Sanofi has halted the development of amlitelimab, an experimental eczema drug it once considered a potential successor to Dupixent, due to mixed late-stage study results and safety concerns. This decision follows similar setbacks for other OX40L-targeting antibodies and raises questions about Sanofi's research pipeline, …

SNY main company
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇺🇸 United States

Eli Lilly Stock In A Buy Zone, Set To Ride The Peptide Wave

Eli Lilly stock hit an all-time high of 1,249.50 before pulling back into a buy zone above a pivot of 1,133.95. Continue Reading

LLY main company
Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3% LLY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Fierce Biotech Deals and strategy Main company 🇺🇸 United States

Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout

Sanofi has decided to abandon its plans to seek approval for amlitelimab, an eczema drug acquired through its $1.1 billion Kymab buyout, for atopic dermatitis. The company stated that the drug would not offer a "meaningful improvement" over existing treatments, despite previous phase 3 …

SNY main company
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
WSJ Regulatory and legal Main company 🇺🇸 United States

Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO

Sanofi has announced it will not seek regulatory approval for its eczema drug, amlitelimab, after data review indicated it doesn't support further development. This decision comes as the French pharmaceutical company undergoes a pipeline review under its new chief executive. While the eczema application …

SNY main company
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
BioSpace Deals and strategy Main company 🇺🇸 United States

Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped

Sanofi has scrapped most of its ongoing trials for amlitelimab, an autoimmune asset acquired from Kymab, in atopic dermatitis following its failure to significantly improve over the standard of care in Phase 3 studies. This decision, part of a strategic pipeline assessment, comes despite …

SNY main company
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Globe and Mail Deals and strategy Main company 🇺🇸 United States

Scilex Announces Strategic Sale of Vivasor Preferred Shares

Scilex Holding Company has announced the strategic sale of over 6.4 million shares of Vivasor’s Series A-1 and A-2 preferred stock back to Vivasor Holding Company. The transaction, valued at approximately $12 million, will be paid to Scilex in multiple tranches through June 30, …

SCLX main company
Sharemaestro market context Trend signal active 52 weeks -42.5% · Next-week setup negative 43.9% SCLX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

Is Novo Nordisk (CPSE:NOVO B) Fully Valued On EU Approval For Its Wegovy Pill?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) is back in focus after the European Commission granted marketing authorisation for its once daily Wegovy pill across all EU member …

NVO main company
Sharemaestro market context Trend signal started 52 weeks -16.7% NVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Seeking Alpha Regulatory and legal Main company 🇺🇸 United States

J&J, Gilead among recipients of EU drug nods this week (JNJ)

The European Medicines Agency's expert panel endorsed 12 new medicines and eight label expansions this week, impacting major pharmaceutical companies. Johnson & Johnson and Gilead are among the U.S. drugmakers receiving positive recommendations for their products. These approvals could allow J&J to enter the …

GILD main company
Sharemaestro market context Price above Trend Line 52 weeks +23.7% GILD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Fierce Pharma Regulatory and legal Main company 🇺🇸 United States

Amgen hands in data package in hopes of FDA hearing for Tavneos defense

Amgen has submitted a data package to the FDA to defend the approval of its ANCA-associated vasculitis drug, Tavneos, which it acquired from ChemoCentryx. The drug faces regulatory scrutiny due to safety flags and concerns about its pivotal trial. Amgen is seeking a hearing …

AMGN main company
Sharemaestro market context Trend signal active 52 weeks +44.4% AMGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Market update Main company 🇺🇸 United States

GSK admits 70,759 shares to trading on London Stock Exchange

GSK plc announced the admission of 70,759 ordinary shares to trading on the London Stock Exchange's Main Market. These shares, part of the GlaxoSmithKline plc Share Save Plan 2022, bring the total number of GSK ordinary shares admitted to trading to 4,316,292,310. The newly …

GSK main company
Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6% GSK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Grifols, S.A. Pref Class B Revenue Breakdown – LSX:A2ABZN

Grifols, S.A. Pref Class B (LSX:A2ABZN) generated 7.52 billion EUR in revenue last year. The Biopharma segment was the top-performing segment, contributing 6.49 billion EUR, an increase from 6.14 billion EUR the previous year. The majority of the company's revenue, 4.25 billion EUR, came …

GRFS main company
Sharemaestro market context Price below Trend Line 52 weeks -23.4% GRFS stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

GSK plc (GSK) adds 70,759 Share Save Plan shares to London listing

GSK plc has announced the admission of 70,759 new ordinary shares to trading on the London Stock Exchange Main Market. These shares are part of the GlaxoSmithKline plc Share Save Plan 2022 and are fully fungible with existing shares. Following this admission, the total …

GSK main company
Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6% GSK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Deals and strategy Main company 🇺🇸 United States

Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?

Biogen is expected to surpass analyst expectations for its Q2 2026 earnings, despite anticipated declines in sales of its established MS drugs like Tecfidera and Tysabri due to generic and biosimilar competition. The company's sales are projected to be bolstered by new product growth …

BIIB main company
Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3% BIIB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Amgen Inc. Revenue Breakdown – HAN:AMG

Amgen Inc. generated €31.29 billion in revenue last year, with Human Therapeutics being its highest-performing segment at €29.93 billion. The United States was the largest regional contributor, accounting for €22.49 billion of the company's revenue. These figures show a slight decrease in overall revenue …

AMGN main company
Sharemaestro market context Trend signal active 52 weeks +44.4% AMGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie (ABBV) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended June 2026, with results anticipated on July 31. The consensus EPS estimate is $3.66 per share (+23.2% year-over-year) and revenues are projected at $16.81 billion (+9%). …

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6% ABBV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Pharmaceutical Technology Earnings Main company 🇺🇸 United States

Sanofi abandons eczema drug approval efforts in another blow to OX40 class

Sanofi has decided to discontinue the development of its immunology therapy, amlitelimab, for atopic dermatitis (AD), citing a lack of meaningful differentiation from existing treatments. This decision is a setback for Sanofi, which had hoped amlitelimab would succeed its blockbuster drug Dupixent, and further …

SNY main company
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Reuters Market update Main company 🇺🇸 United States

Amgen submits new data to challenge FDA's proposal to withdraw Tavneos

Amgen has submitted new data to the FDA to challenge the proposed withdrawal of its rare-disease drug Tavneos from the U.S. market. The company argues that over 70 real-world studies involving more than 2,200 patients support the drug's effectiveness and safety, despite the FDA's …

AMGN main company
Sharemaestro market context Trend signal active 52 weeks +44.4% AMGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
STAT Market update Main company 🇺🇸 United States

Fatal gene-editing trial in China raises ethics and oversight questions

A six-year-old girl has died in China after receiving an experimental, brain-directed CRISPR therapy, sparking significant ethical and oversight concerns. This tragic event was reported in conjunction with other biotech news, including an FDA panel narrowly voting to allow compounding pharmacies to produce certain …

SNY main company
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Ad-hoc-news.de Earnings Main company 🇺🇸 United States

Merck stock steadies as Keytruda drives Q1 2026 revenue growth

Merck & Co.'s stock is primarily driven by its oncology blockbuster Keytruda, which continues to propel revenue growth in Q1 2026. The company is investing billions in R&D to expand its pipeline beyond Keytruda, while also maintaining a significant cash return program. Keytruda remains …

MRK main company
Sharemaestro market context Trend signal active 52 weeks +60.7% MRK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇺🇸 United States

As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab. Continue Reading

NVO main company
Sharemaestro market context Trend signal started 52 weeks -16.7% NVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Seeking Alpha Regulatory and legal Main company 🇺🇸 United States

Merck signs licensing deals for new HIV pill (MRK:NYSE)

Merck has announced seven licensing agreements with generic drug manufacturers, including Viatris, to expand access to its investigational HIV pill, alimatravir. These agreements are aimed at making the drug available in low- and middle-income countries. Three of the companies involved are from sub-Saharan Africa, …

MRK main company
Sharemaestro market context Trend signal active 52 weeks +60.7% MRK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Deals and strategy Main company 🇺🇸 United States

Organon & Co. Shareholders Clear Sun Pharma Merger Deal

Organon & Co. shareholders have approved the proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a special virtual meeting. Shareholders also passed a non-binding advisory vote regarding compensation for executive officers in connection with the merger. The final voting results will be …

OGN main company
Sharemaestro market context Trend signal active 52 weeks +46.5% OGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Dermatology Times Market update Main company 🇺🇸 United States

Sanofi Discontinues Development of OX40L Inhibitor Amlitelimab in Atopic Dermatitis

Sanofi has discontinued the clinical development of amlitelimab for moderate to severe atopic dermatitis (AD), citing insufficient efficacy and safety data to significantly improve upon current standard-of-care treatments. Despite long-term data from the ESTUARY study showing durable maintenance of clinical response, Sanofi concluded that …

SNY main company
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Benzinga Earnings Main company 🇺🇸 United States

CNBC ‘Final Trades’: Netflix, AbbVie, Cerebras Systems - Netflix (NASDAQ:NFLX), CrowdStrike Holdings (NAS

This article summarizes the "Final Trades" segment on CNBC, highlighting stock picks from various financial experts. Recommendations include AbbVie (ABBV) with a raised price target, Transocean (RIG) ahead of earnings, Cerebras Systems (CBRS) due to a new cybersecurity partnership with CrowdStrike (CRWD), and Netflix …

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6% ABBV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Organon's VTAMA Skin-Clearance Response Reached 56.3% in Ages 2–6 at Week 8

Organon (NYSE: OGN) announced new data from a post hoc analysis of its Phase 3 ADORING 1 and 2 trials for VTAMA cream, showing early and consistent improvements in atopic dermatitis across pediatric age groups and adults. The cream demonstrated significant skin clearance and …

OGN main company
Sharemaestro market context Trend signal active 52 weeks +46.5% OGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

First Trust Advisors LP Purchases 108,111 Shares of Biogen Inc. $BIIB

First Trust Advisors LP increased its stake in Biogen Inc. by 19.1% in the first quarter, acquiring an additional 108,111 shares to hold 673,958 shares valued at $123.6 million. This comes as Biogen reported strong quarterly results, beating analyst expectations for EPS and revenue. …

BIIB main company
Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3% BIIB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Johnson & Johnson $JNJ Shares Purchased by Orleans Capital Management Corp LA

Orleans Capital Management Corp LA significantly increased its holdings in Johnson & Johnson (JNJ) by 325.4% in the first quarter, bringing its total to 6,376 shares valued at $1.56 million. This comes as J&J reported strong quarterly results, exceeding analyst expectations for both earnings …

JNJ main company
Sharemaestro market context Trend signal active 52 weeks +48.8% JNJ stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MT Newswires Analyst action Main company 🇺🇸 United States

Market Chatter: Novo Nordisk Seeks Immediate Court Order Against Lilly's Weight-Loss Drug Ads

(Updates with responses from Novo Nordisk and Eli Lilly in the fourth and fifth paragraphs.) Novo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

NVO main company
Sharemaestro market context Trend signal started 52 weeks -16.7% NVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Amgen Inc. $AMGN Shares Sold by Oak Associates Ltd. OH

Oak Associates Ltd. OH reduced its stake in Amgen Inc. by 11.8% in the first quarter, selling 14,795 shares and retaining 110,466 shares valued at approximately $38.9 million. Despite this, Amgen exceeded Q1 earnings estimates with an EPS of $5.15 and revenue of $8.62 …

AMGN main company
Sharemaestro market context Trend signal active 52 weeks +44.4% AMGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Oak Associates Ltd. OH Acquires New Position in Bristol Myers Squibb Company $BMY

Oak Associates Ltd. OH has acquired a new position in Bristol Myers Squibb Company, purchasing 131,790 shares valued at approximately $8.0 million during the first quarter. Bristol Myers Squibb reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, and announced a …

BMY main company
Sharemaestro market context Trend signal active 52 weeks +38.1% BMY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Reuters Market update Main company 🇺🇸 United States

Merck licenses experimental HIV pill to generic makers in 129 countries

Merck has signed voluntary licensing agreements with seven generic drug manufacturers to produce and sell lower-cost versions of its experimental once-monthly oral HIV pill, alimatravir, in 129 low- and lower-middle-income countries. These royalty-free agreements include three sub-Saharan African manufacturers and four Indian companies, covering …

MRK main company
Sharemaestro market context Trend signal active 52 weeks +60.7% MRK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

EU panel recommends Trodelvy-Keytruda after 35% lower progression-or-death risk

Gilead Sciences announced that the European Medicines Agency's CHMP has recommended marketing authorization for Trodelvy in combination with Keytruda for first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. This recommendation is based on the ASCENT-04/KEYNOTE-D19 study, which showed a 35% reduced risk of disease …

GILD main company
Sharemaestro market context Price above Trend Line 52 weeks +23.7% GILD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Forbes Deals and strategy Main company 🇺🇸 United States

This Billionaire Made $360 Million Selling His Psychedelic Company To Eli Lilly

Billionaire Christian Angermayer, inspired by a personal mushroom trip, has sold his psychedelic biotech firm AtaiBeckley to Eli Lilly for $2.8 billion, with potential additional milestone payments. Angermayer's 15% stake is set to net him $360 million (pre-tax). This acquisition, the largest in the …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3% LLY stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context